Aliskiren and HCTZ
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
High Blood Pressure
Conditions
High Blood Pressure
Trial Timeline
Feb 1, 2010 → Oct 1, 2011
NCT ID
NCT01056731About Aliskiren and HCTZ
Aliskiren and HCTZ is a approved stage product being developed by Novartis for High Blood Pressure. The current trial status is completed. This product is registered under clinical trial identifier NCT01056731. Target conditions include High Blood Pressure.
What happened to similar drugs?
5 of 20 similar drugs in High Blood Pressure were approved
Approved (5) Terminated (7) Active (10)
🔄olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimenSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01056731 | Approved | Completed |
Competing Products
20 competing products in High Blood Pressure